دورية أكاديمية

Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.

التفاصيل البيبلوغرافية
العنوان: Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
المؤلفون: Richardson, Paul G, Kumar, Shaji K, Masszi, Tamás, Grzasko, Norbert, Bahlis, Nizar J, Hansson, Markus, Pour, Luděk, Sandhu, Irwindeep, Ganly, Peter, Baker, Bartrum W, Jackson, Sharon R, Stoppa, Anne-Marie, Gimsing, Peter, Garderet, Laurent, Touzeau, Cyrille, Buadi, Francis K, Laubach, Jacob P, Cavo, Michele, Darif, Mohamed, Labotka, Richard
المصدر: Journal of Clinical Oncology; 8/1/2021, Vol. 39 Issue 22, p2430-2442, 13p
قاعدة البيانات: Supplemental Index
الوصف
تدمد:0732183X
DOI:10.1200/JCO.21.00972